|
FDA Suggests 28-Day Primary Endpoint for Clinical Trials of cIAI
Clinical trials of drugs to treat complicated intra-abdominal infections (cIAI) should have a primary endpoint of complete resolution of symptoms at 28 days following randomization and the absence of clinical failure, according to an FDA draft guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives